OncoMatch/Clinical Trials/NCT03936478
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Is NCT03936478 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated and therefore resultant toxicity. The hypothesis is that 3-fraction radiation therapy can be delivered safely without compromising the therapeutic ratio. Participants can expect to be on study for follow up up to 5 years.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Excluded: BRCA1 mutation positivity
BRCA1/2 mutation positivity
Excluded: BRCA2 mutation positivity
BRCA1/2 mutation positivity
Allowed: ESR1 negative
ER (-) [cautionary pathologic factor]
Disease stage
Required: Stage TIS (TNM)
T Stage: Tis or T1 (suitable); T2 (cautionary); Pure DCIS ≤3 cm if 'suitable' criteria not fully met
Prior therapy
Cannot have received: hormonal agent (raloxifene, tamoxifen, aromatase inhibitor, selective estrogen receptor modulator)
Concurrent therapy with any hormonal agents such as raloxifene (Evista®), tamoxifen, Aromatase Inhibitors or other selective estrogen receptor modulators (SERMs), either for osteoporosis or breast cancer prevention or neoadjuvant therapy
Cannot have received: radiation therapy
Prior breast or thoracic radiotherapy for any condition or treatment plan that includes regional nodal irradiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Wisconsin Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify